Business Context and Reporting Period
This Form 8-K, dated January 2, 2014, reports the completion of a merger by Biozone Pharmaceuticals, Inc. ("Biozone"). Effective January 2, 2014, Biozone Acquisitions Co., Inc., a wholly-owned subsidiary of Biozone, merged with and into Cocrystal Discovery, Inc. ("Cocrystal"). Cocrystal continues as the surviving corporation and a wholly-owned subsidiary of Biozone.
Key Financial Metrics and Transaction Details
This filing is a current report regarding a corporate transaction and does not contain standard financial statements, revenue, profit, cash flow, or margin data. Key transaction metrics include:
- Consideration Issued: Biozone issued 1,000,000 shares of Series B Convertible Preferred Stock to Cocrystal security holders.
- Conversion Terms: Series B shares automatically convert into Biozone common stock at a rate of 205.08308640 shares per Series B share once sufficient authorized capital is available.
- Assumed Liabilities: Biozone assumed 4,402,899 outstanding stock options under the Cocrystal 2007 Equity Incentive Plan.
- Executive Compensation: New employment agreements were executed with annual salaries of $250,000 for the CEO and $180,000 for the President, plus significant stock option grants.
Material Changes Versus Prior Period
The filing details a complete restructuring of the company's leadership and capital structure:
- Board Composition: The Board of Directors was reconstituted to six members. Dr. Gary Wilcox, Dr. Sam Lee, Dr. Roger Kornberg, Dr. Phillip Frost, Dr. Jane Hsiao, and Steven Rubin were appointed. Elliot Maza, Roberto Prego-Novo, and Brian Keller resigned.
- Executive Management: Pre-merger executives Elliot Maza, Brian Keller, and Christian Oertle resigned. New officers appointed include Gary Wilcox (CEO and Secretary), Sam Lee (President), and Gerald McGuire (CFO and Treasurer).
- Capital Structure: A new class of equity, Series B Convertible Preferred Stock, was designated and issued.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, revenue outlook, or management commentary on future performance. However, it notes the following contingencies and risks:
- Unregistered Securities: The Series B shares were issued under Section 4(a)(2) and Rule 506(b) exemptions and are not registered under the Securities Act of 1933. They may not be offered or sold in the U.S. without an effective registration statement or exemption.
- Option Vesting: Significant stock option grants to the new CEO and President vest over time, with 25% vesting on January 2, 2015, and the remainder vesting in 36 equal monthly increments thereafter.
Important Facts for Investor Verification
- Verify the exact conversion ratio of Series B Preferred Stock to common stock and the timeline for Biozone to obtain sufficient authorized capital.
- Confirm the total number of outstanding shares post-merger, including the impact of the 4.4 million assumed options and new executive grants.
- Review the full text of the Merger Agreement (Exhibit 2.1) for any additional covenants or conditions not summarized in this report.
- Assess the financial impact of the new executive compensation packages, specifically the $250,000 and $180,000 base salaries and associated bonus targets.